There were 1,757 press releases posted in the last 24 hours and 260,410 in the last 365 days.

DIAGNOS Inc. Expands Artificial Intelligence Platform into Early Detection of Cardiovascular Disease

Retinal image enhanced with DIAGNOS software, prepped for A.I. auto-detection of pathology & lesion classification.

DIAGNOS Inc. (TSX-V: ADK) positions itself as first-mover with major upside potential in a near US$400B/annum market place.


Using artificial intelligence in healthcare saves government and healthcare services money by preventing debilitating blindness in at-risk populations.”
— F. William, Market Equities Research Group

NEW YORK, NY, UNITED STATES, September 22, 2017 / -- DIAGNOS Inc. (TSX-V: ADK) (US Listing: DGNOF) (Frankfurt: 4D4) is a Canadian-based healthcare software technology company, its 'Computer Assisted Retinal Analysis' (CARA) business has been successfully applying artificial intelligence in the diabetes market for several years via non-invasively identifying patients at risk of vision loss. The Company is the subject of a Market Equities Research Group Market Bulletin with a near-term (12-month) $1/share price target for ADK.V, copy of which is available at online. The Company is active in 15 countries in total for installations of its CARA technology platform worldwide, this number and related metrics are only just getting started with the company in the early stages of a vertical growth trajectory. On September 19, 2017 the Company announced an expansion of its platform into early detection of Cardiovascular Disease.

DIAGNOS Inc.'s proprietary artificial intelligence algos continually learn and refine analytics from large data sets. If results from the newly announced move into cardiovascular disease (CVD) are anything similar to the success DIAGNOS has achieved with early detection of diabetes, it will affirm the Company has effectively cracked the key to early detection of heart disease via computer assisted retinal analysis, and the potential implications for shareholders of ADK.V are enormous, with dramatic upward share price appreciation being a certainty.

The newly announced calibration of the application for CVD will be done simultaneously in 4 countries (Algeria, Canada, Mexico and United States) with a minimum of 1,000 in each country with the support of 22 cardiologists. This will enable Diagnos to insure the sustainability of its solution worldwide.

Diagnos' current market cap (currently ~$20 million Canadian for ADK.V trading at 12 cents) is miniscule compared to its potential. Success in early detection of heart disease in such a non-invasive manner (for the patient), and disruptive to the marketplace, similar to that which Diagnos Inc. has already proven it is able to do for diabetes, will quickly result in the Company being a primary go-to service in a massive market place that currently spends near US$400 Billion a year in drugs and services for cardiovascular and stroke issues.

The following additional research links have been identified for further DD on DIAGNOS Inc.:
- DIAGNOS’ corporate website:
- Recent Journal review:
- Q2 research report:
(Note: the above Q2 research report places a 12-month $1/share price target on ADK.V based on the Company’s CARA platform targeting diabetes alone).

This release may contain forward-looking statements regarding future events that involve risk and uncertainties. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual events or results. Readers are cautioned that not until subject companies actually releases official details themselves should anyone rely on the information presented herein. Articles, excerpts, commentary and reviews herein are for information purposes and are not solicitations to buy or sell any of the securities mentioned.

Fredrick William
Market Equities Research Group
email us here